SrasV1, Ncbi, Curation, bibRecord, 001B61

SARS coronavirus anti-infectives.

Identifieur interne : 001B61 ( Ncbi/Curation ); précédent : 001B60; suivant : 001B62

SARS coronavirus anti-infectives.

Auteurs : Tommy R. Tong [Hong Kong]

Source :

Recent patents on anti-infective drug discovery [ 1574-891X ] ; 2006.

RBID : pubmed:18221155

Descripteurs français

KwdFr :
- Animaux, Anticorps monoclonaux (pharmacologie), Antiviraux (usage thérapeutique), DNA-directed RNA polymerases (antagonistes et inhibiteurs), Helicase (antagonistes et inhibiteurs), Humains, Inhibiteurs de protéases (pharmacologie), Interférons (pharmacologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (pathogénicité).
MESH :
- antagonistes et inhibiteurs : DNA-directed RNA polymerases, Helicase.
- pathogénicité : Virus du SRAS.
- pharmacologie : Anticorps monoclonaux, Inhibiteurs de protéases, Interférons.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Humains, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Antibodies, Monoclonal (pharmacology), Antiviral Agents (therapeutic use), DNA Helicases (antagonists & inhibitors), DNA-Directed RNA Polymerases (antagonists & inhibitors), Humans, Interferons (pharmacology), Protease Inhibitors (pharmacology), SARS Virus (drug effects), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology).
MESH :
- chemical , antagonists & inhibitors : DNA Helicases, DNA-Directed RNA Polymerases.
- chemical , pharmacology : Antibodies, Monoclonal, Interferons, Protease Inhibitors.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Humans.

Abstract

Severe acute respiratory syndrome (SARS) emerged in late 2002 and was controlled in July 2003 by public health measures. Its causative agent, SARS coronavirus (SARS-CoV) jumped from an animal reservoir to humans and has the potential to re-emerge. Following the sequencing of the genetic code and the deciphering of some of the functions of its proteins, including the cellular receptors and host proteins that participate in the life cycle of the virus, promising lead drugs and new uses of old drugs have been discovered. Patent applications for cathepsin L inhibitors have taken new relevance because of the role of cathepsin L in the entry of SARS-CoV into host cells. Likewise, patent applications for SARS-CoV protease inhibitors and interferon and mismatched dsRNA also need to be watched for potential application in treatment and prevention of SARS-CoV. Here, we review the recent advances and inventions that target SARS-CoV infection in humans.

DOI: 10.2174/157489106778777637
PubMed: 18221155

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C31
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001C31
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002025
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001B61

Links to Exploration step

pubmed:18221155

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS coronavirus anti-infectives.</title>
<author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Princess Margaret Hospital, Hong Kong. tommy.tong@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>Department of Pathology, Princess Margaret Hospital</wicri:regionArea>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:18221155</idno>
<idno type="pmid">18221155</idno>
<idno type="doi">10.2174/157489106778777637</idno>
<idno type="wicri:Area/PubMed/Corpus">001C31</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C31</idno>
<idno type="wicri:Area/PubMed/Curation">001C31</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C31</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002025</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002025</idno>
<idno type="wicri:Area/Ncbi/Merge">001B61</idno>
<idno type="wicri:Area/Ncbi/Curation">001B61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS coronavirus anti-infectives.</title>
<author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Princess Margaret Hospital, Hong Kong. tommy.tong@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>Department of Pathology, Princess Margaret Hospital</wicri:regionArea>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Recent patents on anti-infective drug discovery</title>
<idno type="ISSN">1574-891X</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>DNA Helicases (antagonists & inhibitors)</term>
<term>DNA-Directed RNA Polymerases (antagonists & inhibitors)</term>
<term>Humans</term>
<term>Interferons (pharmacology)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps monoclonaux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>DNA-directed RNA polymerases (antagonistes et inhibiteurs)</term>
<term>Helicase (antagonistes et inhibiteurs)</term>
<term>Humains</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Interférons (pharmacologie)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Helicases</term>
<term>DNA-Directed RNA Polymerases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Interferons</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>DNA-directed RNA polymerases</term>
<term>Helicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Inhibiteurs de protéases</term>
<term>Interférons</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) emerged in late 2002 and was controlled in July 2003 by public health measures. Its causative agent, SARS coronavirus (SARS-CoV) jumped from an animal reservoir to humans and has the potential to re-emerge. Following the sequencing of the genetic code and the deciphering of some of the functions of its proteins, including the cellular receptors and host proteins that participate in the life cycle of the virus, promising lead drugs and new uses of old drugs have been discovered. Patent applications for cathepsin L inhibitors have taken new relevance because of the role of cathepsin L in the entry of SARS-CoV into host cells. Likewise, patent applications for SARS-CoV protease inhibitors and interferon and mismatched dsRNA also need to be watched for potential application in treatment and prevention of SARS-CoV. Here, we review the recent advances and inventions that target SARS-CoV infection in humans.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B61 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001B61 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:18221155
   |texte=   SARS coronavirus anti-infectives.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:18221155" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

SARS coronavirus anti-infectives.

SARS coronavirus anti-infectives.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki